Conatumumab

• CAT Number: I042443
• CAS Number: 896731-82-1
• Molecular Weight: 145.65 (kDa)
• Purity: ≥95%

Conatumumab (Cat No.: I042443) is a fully human monoclonal antibody that targets death receptor 5 (DR5), a member of the tumor necrosis factor receptor superfamily involved in apoptosis. By binding to DR5, conatumumab activates the extrinsic apoptotic pathway, selectively inducing cell death in cancer cells expressing this receptor. It has been investigated in clinical trials for treating various malignancies, including colorectal, non-small cell lung, and pancreatic cancers. Conatumumab represents a promising therapeutic approach in oncology, particularly for tumors resistant to conventional therapies.

Reference

[1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91.
[Content Brief]

[2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.
[Content Brief]